COMP <GO>
CRSP vs MRK // EV/EBITDA & P/E VALUATION
CRISPR Therapeutics AG (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: CRSP 2
— MRK 12
■ METRIC PARITY
LAST: $51.42 (-5.23%) • MKT CAP: $5.25B
valuation
—
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRSP VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRSP | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -30.60% | 20.70% | -51.30 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.59% | 3.42% | -10.01 | MRK | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.30% | -94.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.10% | -88.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 1.30% | -66.30 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.97 | 5.19 | +2.78 | CRSP | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 6.60% | +0.70 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.6 | 56.9 | -9.26 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.12 | 0.92 | +0.20 | CRSP | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | 18.4x | +9.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.25B | $361.02B | -$355.77B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRSP REV | MRK REV | CRSP GROSS % | MRK GROSS % | CRSP FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.5M | $65.01B | 44.0% | 74.8% | -$345.9M | $12.36B |
| FY 2024 | $37.3M | $64.17B | 44.0% | 76.3% | -$144.7M | $18.10B |
| FY 2023 | $371.2M | $60.12B | 44.0% | 44.0% | -$277.1M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRSP // BETA 1.12
MRK // BETA 0.92